Value Investors: Buy Canada’s Best Pharmaceutical Stock

CRH Medical Corporation (TSX:CRH) could become a market leader in the gastrointestinal business. Investors could still purchase the stock, as higher acquisition offers than the one recently made are likely.

| More on:
Pills spilling out of a prescription pot

Image source: Getty Images.

CRH Medical (TSX:CRH) is a North American company focused on providing physicians throughout the United States with innovative products and services for the treatment of gastrointestinal (GI) diseases. The company distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves.

A few days back, WELL Health Technologies (TSX:WELL) recently announced a deal to acquire CRH for $369.2 million. This is expected to be a wonderful acquisition for WELL Health, which is raising equity from several high-profile investors, including Mr. Li Ka-shing, Hong Kong’s most famous business tycoon, to fund the purchase. WELL Health is expected to raise equity at a 25% premium to the volume weighted average price due to significant investor demand.

At the acquisition price, CRH is valued a price-to-earnings ratio of 97.60, price-to-book ratio of 4.83, and market capitalization of $349 million. Debt is very sparingly used at CRH, as evidenced by a debt-to-equity ratio of just 0.96. Prior to the takeover offer, CRH reported depressed performance metrics with an operating margin of (7.95)% and a return on equity of (2.6)%.

The CRH O’Regan System is a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. In 2014, CRH acquired Gastroenterology Anesthesia Associates (GAA), a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures. Performing these procedures under anesthetic provides more comfort for patients. CRH has continued to leverage the capabilities it acquired through GAA to consolidate the highly fragmented gastroenterology anesthesia provider business.

CRH’s goal is to establish itself as the premier provider of innovative products and essential services to gastroenterologists. The company has been on a shopping spree over the last five years, buying up anesthesia services providers in the United States. Most recently, CRH acquired 100% of certain assets of Anesthesia Care Associates, an anesthesia services provider in Indiana.

The company’s management, medical and support teams have developed specific skills and knowledge in the United States (U.S.) healthcare market. The extent and breadth of CRH’s experience delivering healthcare services, developed through years of operating across multiple U.S. states, have provided it with a national scope of knowledge that is not easily acquired or replicated.

CRH’s management has acquired the knowledge necessary to gather and process the critical information required to enter prospective markets. The company has developed this knowledge and expertise by acquiring new personnel with the requisite skill sets.

CRH outsources design and manufacturing activities to save on costs. However, the company maintains direct control over customer service activities to ensure that it provides the best service to customers. Through an established system of customer feedback, CRH monitors for signs of quality problems and customer issues. CRH has also established a feedback system to provide early warning of quality problems and to determine whether it has met the customer’s requirements.

In summary, CRH could become a market leader in the gastrointestinal business which could result in a significantly higher stock price. Investors could still purchase the stock, as higher acquisition offers than the one made by WELL Health are likely.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned. The Motley Fool owns shares of CRH Medical.

More on Investing

Man considering whether to sell or buy
Bank Stocks

Is TD Stock a Buy, Sell, or Hold?

TD stock just bounced. Are more gains on the way?

Read more »

grow money, wealth build
Dividend Stocks

5 “Forever” Dividend Stocks to Build Your Wealth

If you're looking for dividend stocks you can happily hold forever, consider these five. Some with more growth in returns…

Read more »

The sun sets behind a power source
Dividend Stocks

3 Reasons Why Canadian Utilities Is an Ideal Canadian Dividend Stock

Canadian Utilities (TSX:CU) stock is well known as a dividend star, but why? Let's get into three reasons why it's…

Read more »

Gas pipelines
Energy Stocks

TSX Energy in April 2024: The Best Stocks to Buy Right Now

Energy prices have soared higher than expected. That is a big plus for Canadian energy stocks. Here are three great…

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Thursday, April 25

TSX investors will focus on the first-quarter U.S. GDP growth numbers and more corporate earnings today.

Read more »

rail train
Stocks for Beginners

CP Stock: 1 Key Catalyst Investors Should Watch

After a positive surprise in the last quarter, CP stock (TSX:CP) recently made a change that should have investors excited…

Read more »

Payday ringed on a calendar
Dividend Stocks

Cash Kings: 3 TSX Stocks That Pay Monthly

These stocks are rewarding shareholders with regular monthly dividends and high yields, making them compelling investments for monthly cash.

Read more »

grow dividends
Tech Stocks

Celestica Stock Is up 62% in 2024 Alone, and an Earnings Pop Could Bring Even More

Celestica (TSX:CLS) stock is up an incredible 280% in the last year. But more could be coming when the stock…

Read more »